Annual General Meeting Of Q-Med AB (publ).UPPSALA, Sweden -- The Annual General Meeting of Q-Med AB (publ) (STO:QMED) was held on May 3, 2007 at 3 p.m. on Q-Med's new premises, which are entered from Fyrisvallsgatan 5, Uppsala. Dividend The meeting decided that a dividend of 2 SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. per share shall be paid to shareholders. Board and fees The meeting decided to re-elect re·e·lect also re-e·lect tr.v. re·e·lect·ed, re·e·lect·ing, re·e·lects To elect again. re the following members of the Board, Hakan Edstrom, Bertil Hult, Anders Milton, Pia Rudengren, Asa Roden, Pernilla Strom och Bengt Agerup for the period up until the end of the next Annual General Meeting. The meeting also re-elected Pia Rudengren as the Chair of the Board. The meeting also decided that Board fees of 1,050,000 SEK in total be paid for the period 2007/2008, with 300,000 SEK to the Chair of the Board and 150,000 SEK to each of the other members of the Board, except for Bengt Agerup, who is an employee of the company and shall therefore not receive a Board fee, which means unchanged fees compared with the previous year. Auditors' fees shall be paid in accordance with reasonable invoicing. A fee of 180,000 SEK in total shall be paid for work on the audit committee, to be divided among the three members as follows: 90,000 SEK to the Chair of the committee and 45,000 SEK to each of the other two committee members. Election committee The Annual General Meeting decided that the election committee shall continue to consist of three members and re-elected Robert Wikholm as Chair with the assignment of finding, at the latest during the third quarter, two representatives from the major owners to be included in the election committee, and that a fee of SEK 60,000 be paid to the election committee, to be allocated in accordance with the decision of the election committee. This is an unchanged fee compared with the previous year. Principles for remuneration Finally, the meeting decided on principles for remuneration and other conditions of employment conditions of employment that part of an employment that sets out the duties, responsibilities, hours of work, salary, leave and other privileges to be enjoyed by persons employed, for example a veterinary nurse, in private practice. for senior management in accordance with the proposal of the Board. Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA NASHA Non-Animal, Stabilized Hyaluronic Acid (trademark of Q-Med AB; Uppsala, Sweden) NASHA National Association for Speech and Hearing Action (Rockville, MD) [TM] for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR VUR Vesicoureteral reflux, see there , (a malformation malformation /mal·for·ma·tion/ (-for-ma´shun) 1. a type of anomaly. 2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap segment of the OMX OMX Office Max (stock symbol) Nordic Stock Exchange in Stockholm. NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med AB. This information was brought to you by Cision http://newsroom.cision.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion